Tumour DNA in the blood can predict lung cancer outcome

Circulating tumour DNA (ctDNA) describes fragments of DNA that have been released into the blood by tumours. ctDNA is known to be important for disease prognosis, but can be difficult to measure precisely.

In a CRUK-funded study published in Nature Medicine, UCL and Crick scientists worked with biotechnology company Personalis to test a platform called NeXT Personal, which can detect very small amounts (1 part per million) of ctDNA. This builds on the team’s previous discovery of signals in the blood that detect cancer cells after treatment, which could indicate a potential for relapse.

The researchers applied the platform to blood plasma samples from 171 people with early-stage lung cancer in the TRACERx cohort, finding that people with a low level of ctDNA before surgery were less likely to relapse and had improved overall survival rates compared to people with a high level of ctDNA.

The high sensitivity of the test meant that smaller amounts of ctDNA could be detected, which prevented people with a lower amount of ctDNA from being incorrectly labelled ‘ctDNA negative’.

Early-stage lung cancer is usually treated by removing the tumour by surgery and with chemotherapy or immunotherapy, depending on the stage of the tumour, which aims to achieve the highest chance of cure.

The test will next be assessed on samples from patients that have undergone surgery with the earliest stages of lung cancer, to evaluate if the presence of ctDNA post-operatively in the blood can be used to infer future risk of relapse. This could allow doctors to offer additional therapy after surgery, increasing the chance of curing patients.

Dr James Black, first author of the study from the CRUK Lung Cancer Centre of Excellence at UCL and a Postdoctoral Clinical Fellow at the Francis Crick Institute, said: “We’ve shown that the presence or absence of tumour DNA in the blood was strongly predictive of prognosis. ctDNA testing, especially using ultrasensitive platforms, could help clinicians make more informed decisions about treatment and give patients a more accurate idea of how their disease might progress. More research to validate these tests will help to get them on the agenda for regular clinical use.”

Professor Charles Swanton, Chief Investigator of the CRUK TRACERx study from UCL Cancer Institute, the Crick and UCLH, and senior author of the study, said: “Lung cancer is one of the most common types of cancer in the UK, but it’s hard to treat with a high relapse rate. It’s vital to understand who would benefit from more aggressive treatment, especially for patients with Stage 1 disease who are often diagnosed during CT screening for those at a higher risk. Using sensitive ctDNA tests is one way to do this, which we hope will maximise clinical benefit and minimise unnecessary treatment for individual patients.”

Richard Chen, Chief Medical Officer and Executive Vice President of Research & Development at Personalis, said: “We designed NeXT Personal to detect residual or recurrent cancer in its earliest stages, and this study shows the clinical importance of that ultra-sensitive detection in early-stage lung cancer. A more sensitive test like NeXT Personal offers the potential of earlier detection and earlier treatment for patients. Similarly, as we see in this study, a negative test can potentially reassure patients, and offer the hope of avoiding unnecessary therapy in the future."

Marianne Baker, Research Information Manager at Cancer Research UK, said: "TRACERx is our flagship lung cancer research study, tracking the disease’s evolution over time. As a hard-to-treat cancer, the more we understand about its progression, the better equipped we are to beat it.

 "The kind of test used in NeXT Personal can help us move toward an age of personalised medicine, ensuring clinicians can get the right treatment to the right people by accurately sorting them into groups based on what their disease is likely to do. The test can help to improve quality of life and survival by ensuring clinicians can go all-in for people whose disease is more likely to come back after treatment, while sparing people difficult treatments they might not need if their disease is less risky.

 "More research is needed, but the study takes us a step closer to a day where treatments can be tailored to patients. The next chapter in TRACERx, TRACERx EVO, is now recruiting people to join the study and will be looking even deeper into the biology of lung cancer."

The study is supported by the National Institute for Health and Care Research UCLH Biomedical Research Centre.

Links

• Professor Charles Swanton's academic profile
• Dr James Black's academic profile
• UCL Cancer Institute
• UCL Faculty of Medical Sciences
• The Francis Crick Institute

Image

• Credit: ktsimage on iStock

Media contact 

Dr Matt Midgley

E: m.midgley [at] ucl.ac.uk